Three-year data for Iluvien found a single implant delayed recurrence of noninfectious posterior uveitis and reduced uveitis symptoms, according to a press release from Alimera Sciences.
The phase 3 clinical trial showed the median time to first recurrence of noninfectious uveitis affecting the posterior of the eye was 657 days, or 94 weeks, in patients treated with Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) compared with 70.5 days, or 10 weeks, in those treated with sham (P < .001). In addition, the Iluvien arm saw 1.7 uveitis recurrences compared with (Read more...)
Uncategorized